Drug Trial Radar · NCT05035212
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
38,861
Actual
Start
Aug 31, 2021
Primary completion
Jan 18, 2027
Study completion Jan 18, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This study is an extension of the efficacy study and was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 2 years: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 18 months. * The study will be conducted in the United States and Argentina. Substudy B: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 1 year: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 18 months. * The study will be conducted in Argentina. Substudy C: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of either 3 or 4 years: * At a dose of 120µg (as studied in the Phase 3 Efficacy Study) * Participants will receive either placebo or a second dose of RSVpreF approximately 3 or 4 years after receiving the initial dose of RSVpreF in the main efficacy study. * Blood samples will be collected for antibody testing. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States and Canada.
Conditions
- Lower Respiratory Tract Illness
Interventions
RSVpreFBiological
RSV vaccine (RSVpreF)
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Study: Number of first episode of RSV-associated lower respiratory tract illness (LRTI-RSV) in the first RSV seasonTime frame: From Day 15 after vaccination until the end of season 1 visit (an average of 6 months)
- Efficacy Study: Proportion of participants reporting prompted local reactions within 7-days after vaccinationTime frame: Within 7 days after vaccination
- Efficacy Study: Proportion of participants reporting prompted systemic events within 7-days after vaccinationTime frame: Within 7 days after vaccination
- Efficacy Study: Proportion of participants reporting AE within 1-month after vaccinationTime frame: Within 1 month after vaccination (up to 35 days)
- Efficacy Study: Proportion of participants reporting SAE throughout the studyTime frame: Throughout the study duration (an average of 30 months)
- Efficacy Study: Proportion of participants reporting NDCMC throughout the studyTime frame: Throughout the study duration (an average of 30 months)
- SSA: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 2-dose of RSVpreFTime frame: Before revaccination and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSA
- SSA: Proportion of participants reporting prompted local reactions within 7-days after revaccinationTime frame: Within 7 days after revaccination
- SSA: Proportion of participants reporting prompted systemic events within 7-days after revaccinationTime frame: Within 7 days after revaccination
- SSA: Proportion of participants reporting AE within 1-month after revaccinationTime frame: Within 1 month after revaccination (up to 35 days)
- SSA: Proportion of participants reporting SAE throughout the studyTime frame: Throughout the study duration (approximately 18 months)
- SSA: Proportion of participants reporting NDCMC throughout the studyTime frame: Throughout the study duration (approximately 18 months)
- SSB: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 2-dose of RSVpreFTime frame: Before revaccination and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSB
- SSB: Proportion of participants reporting prompted local reactions within 7-days after revaccinationTime frame: Within 7 days after revaccination
- SSB: Proportion of participants reporting prompted systemic events within 7-days after revaccinationTime frame: SSB: Proportion of participants reporting prompted systemic events within 7-days after revaccination
- SSB: Proportion of participants reporting AE within 1-month after revaccinationTime frame: Within 1 month after revaccination (up to 35 days)
- SSB: Proportion of participants reporting SAE throughout the studyTime frame: Throughout the study duration (approximately 18 months)
- SSB: Proportion of participants reporting NDCMC throughout the studyTime frame: Throughout the study duration (approximately 18 months)
- SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF or placebo in SSC (Year 3)Time frame: 1 month after revaccination in SSC (Year 3)
- SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 1 dose in the Main Efficacy Study (preS2) and revaccination in SSC (Year 3)Time frame: At preseason 2 (preS2) after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 3)
- SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 1 dose in the Main Efficacy Study and revaccination in SSC (Year 3)Time frame: 1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 3)
- SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF or placebo in SSC (Year 4)Time frame: 1 month after revaccination in SSC (Year 4)
- SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 1 dose in the Main Efficacy Study (preS2) and revaccination in SSC (Year 4)Time frame: At preseason 2 (preS2) after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 4)
- SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 1 dose in the Main Efficacy Study and revaccination in SSC (Year 4)Time frame: 1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 4)
- SSC: Proportion of participants reporting prompted local reactions within 7-days after revaccination (Year 3)Time frame: Within 7 days after revaccination
- SSC: Proportion of participants reporting prompted local reactions within 7-days after revaccination (Year 4)Time frame: Within 7 days after revaccination
- SSC: Proportion of participants reporting prompted systemic events within 7-days after revaccination (Year 3)Time frame: Within 7 days after revaccination
- SSC: Proportion of participants reporting prompted systemic events within 7-days after revaccination (Year 4)Time frame: Within 7 days after revaccination
- SSC: Proportion of participants reporting AE within 1-month after revaccination (Year 3)Time frame: Within 1 month after revaccination (up to 35 days)
- SSC: Proportion of participants reporting AE within 1-month after revaccination (Year 4)Time frame: Within 1 month after revaccination (up to 35 days)
- SSC: Proportion of participants reporting SAE after revaccination (Year 3)Time frame: Following revaccination and throughout the study duration (approximately 24 months)
- SSC: Proportion of participants reporting SAE after revaccination (Year 4)Time frame: Following revaccination and throughout the study duration (approximately 12 months)
- SSC: Proportion of participants reporting NDCMC after revaccination (Year 3)Time frame: Following revaccination and throughout the study duration (approximately 24 months)
- SSC: Proportion of participants reporting NDCMC after revaccination (Year 4)Time frame: Following revaccination and throughout the study duration (approximately 12 months)
Locations
263 sites in 7 countries. Site status is shown where the registry gives one.
St. Vincent's Birmingham (Pharmacy)
Birmingham, Alabama
St. Vincent's Birmingham
Birmingham, Alabama
Medical Affiliated Research Center
Huntsville, Alabama
Lenzmeier Family Medicine / Avacare
Glendale, Arizona
Phoenix Clinical LLC
Phoenix, Arizona
HOPE Research Institute
Phoenix, Arizona
The Pain Center of Arizona
Phoenix, Arizona
HOPE Research Institute
Phoenix, Arizona
Cognitive Clinical Trials, LLC
Phoenix, Arizona
Headlands Research - Scottsdale
Scottsdale, Arizona
Alliance for Multispecialty Research, LLC
Tempe, Arizona
HOPE Research Institute
Tempe, Arizona
Noble Clinical Research
Tucson, Arizona
The Institute for Liver Health dba Arizona Clinical Trials
Tucson, Arizona
Hope Clinical Research
Canoga Park, California
eStudySite
Chula Vista, California
Benchmark Research
Colton, California
West Coast Research
Dublin, California
Marvel Clinical Research 002, LLC
Huntington Beach, California
Chemidox Clinical Trials
Lancaster, California
Ark Clinical Research
Long Beach, California
Downtown L.A. Research Center, Inc.
Los Angeles, California
Velocity Clinical Research, North Hollywood
North Hollywood, California
Clinica mi Salud by Focil Med
Oxnard, California
De Silva Medical Inc
Palmdale, California
Empire Clinical Research
Pomona, California
Paradigm Clinical Research Center
Redding, California
Artemis Institute for Clinical Research
Riverside, California
Benchmark Research
Sacramento, California
Artemis Institute for Clinical Research
San Diego, California
California Research Foundation
San Diego, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Lynn Institute of Denver
Aurora, Colorado
Tekton Research LLC
Longmont, Colorado
Clinical Research Consulting
Milford, Connecticut
Stamford Therapeutics Consortium
Stamford, Connecticut
JEM Research Institute
Atlantis, Florida
IDEAL Clinical Research
Aventura, Florida
Innovative Research of West Florida
Clearwater, Florida
Invictus Clinical Research Group, LLC
Coconut Creek, Florida
Showing 40 of 263 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.